Liu Wei

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and RNA Editing

Retrieved on: 
Tuesday, April 23, 2024
Sequence, Small RNA, RNA editing, Potency, Durability, Health, ...Continued, RNA, MD, Doctor of Philosophy, Weight loss, IND, CNS, Obesity, Oligonucleotide, GSK, Patient, Medicinal chemistry, MBA, Liu Wei, Clinical trial, Pharmaceutical industry

CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today provided an update on its best-in-class small interfering RNA (siRNA) and RNA editing platform capabilities.

Key Points: 
  • As part of Wave’s ongoing collaboration with GSK, GSK has selected its first two programs to advance to development candidates following achievement of target validation.
  • GSK will provide an aggregate initiation payment of $12 million to Wave for these two oligonucleotide programs.
  • Under the agreement, GSK can advance up to eight programs leveraging Wave’s PRISM™ platform and multiple RNA-targeting modalities (RNA editing, splicing, siRNA, and antisense) with target validation work ongoing across multiple therapy areas.
  • Beyond these programs, our collaboration is focusing on all Wave modalities, including RNA editing.

Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting

Retrieved on: 
Tuesday, May 16, 2023
Medicinal chemistry, Liver disease, Wave, PDT, CTA, Gene expression, RNA, Doctor of Philosophy, Liu Wei, Small RNA, Chemistry, AATD, DMD, HSD17B13, Annual general meeting, Cell, PAS-D, ISCB Senior Scientist Award, Mouse, Liver, AAT, Society, Oligonucleotide, Biology, Hepatitis, Dietary supplement, Vaccine, Communications satellite, Forestry, Flour

CAMBRIDGE, Mass., May 16, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced it will highlight its leading RNA editing capability and its multimodal discovery and development platform at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place May 16-20, 2023, in Los Angeles, California.

Key Points: 
  • New preclinical data for WVE-006, Wave’s investigational, GalNAc-conjugated RNA editing candidate for the treatment of alpha-1 antitrypsin deficiency (AATD), will be presented in an oral abstract session.
  • Additionally, Wave will present preclinical data in a poster session regarding the ability of ADAR-mediated RNA editing to upregulate gene expression.
  • Wave is pioneering this novel editing application with potential to address diseases with large patient populations, independent of genetic mutation status.
  • “The ingenuity of our scientists has resulted in a best-in-class RNA medicines platform and the industry’s most advanced and promising RNA editing capability.